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Abstract
Background: Women with type 2 diabetes mellitus (T2DM) have a higher risk of fractures despite increased bone
mineral density (BMD). In experimental studies a potential role of plasminogen activator inhibitor-1 (PAI-1) in bone
remodeling is suggested but studies in humans are lacking. This is a first study in humans investigating whether
circulated levels of PAI-1 in postmenopausal women with T2DM are related to BMD and adiposity.
Methods: Anthropometric variables, PAI-1 and insulin levels, serum lipids and bone turnover markers were
measured in 127 postmenopausal women with T2DM. A total of 117 female patients were divided according to
lumbar spine BMD measurements via dual-energy x-ray absorptiometry in three groups: 47 with osteopenia, 21
with osteoporosis and 49 with normal BMD.
Results: Diabetic patients with normal BMD had significantly higher BMI, greater waist circumference and lower bone
turnover markers than diabetics with osteopenia and osteoporosis. PAI-1 was lower in diabetics with osteoporosis and
osteopenia compared with diabetics with normal BMD. Multiple regression analysis revealed insulin, triglycerides levels,
pyrilinks and beta blocker therapy to be the strongest predictors of PAI-1 levels. PAI-1 levels correlated with both
L-BMD and hip BMD, but after adjustment for age and BMI association was no longer significant.
Conclusion: Our findings suggest that elevated PAI-1 levels are associated with higher BMD in obese diabetic
patients but the possible implications of this finding and underlying mechanisms still remain unclear. Obviously,
metabolic parameters, may affect both BMD and PAI-levels, and association of PAI-1 and BMD could be indirect.
However, as pyrilinks is also independently and significantly negatively correlated to PAI-1 its direct involvement
in bone metabolism is also plausible. Further investigations are needed to elucidate the nature of interaction of
this matrix modulator in relation to energy and bone metabolism in humans.
Keywords: Diabetes type 2, Plasminogen activator inhibitor-1, Bone mineral density, Bone turnover markers,
Osteoporosis, Osteopenia
* Correspondence: prpic-krizevac.ivana@kbco.hr
Department of Diabetes, Endocrinology and Metabolism Disorders, University
Hospital Center Osijek, Faculty of Medicine, University of Osijek, J. Huttlera 4,
HR-31000 Osijek, Croatia
© 2016 Canecki-Varžić et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Canecki-Varžić et al. BMC Endocrine Disorders  (2016) 16:14 
DOI 10.1186/s12902-016-0094-x
Background
Diabetes mellitus type 2 (T2DM) could influence bone
through several mechanisms, some of which may have
contradictory effects. Traditionally it is thought that
obesity or high body mass index (BMI) has a beneficial
effect on bone mass thus protecting against excessive
bone loss in aging [1, 2]. This is probably a result of
enhanced osteoblast differentiation due to heavier mech-
anical loading of bone, whereas hyperinsulinemia may
promote bone formation [3]. However, previous studies
have suggested that bone quality is poor in diabetic patients
causing impaired fracture healing, but underlying mecha-
nisms remain unclear. One of the possibilities is increased
resorption or suppressed bone turnover mediated through
low-grade inflammation present in diabetes type 2 [4, 5].
One of those proinflammatory cytokines is plasminogen
activator inhibitor-1 (PAI-1) and its increased levels are
present in patients with diabetes type 2 and metabolic syn-
drome [6, 7], while adipose tissue is a significant determin-
ant of PAI plasma concentration [8–10]. Furthermore,
increased PAI-1 activity has been associated with polycystic
ovarian syndrome (PCOS) as well as with the progression
of atherosclerosis [11]. Also, PAI is a recognized modulator
of matrix and could be implicated in the bone homeostasis
through regulation of bone size during developmental
growth and determination of fracture callus size, cartilage
formation, and resorption during bone fracture repair as
was shown in murine model [12, 13]. Obviously, there is
growing evidence of the importance of PAI in bone metab-
olism, however studies in humans are lacking in particular
in patients with osteoporosis. The aim of this study was to
investigate whether circulated levels of PAI-1 in postmeno-
pausal women with T2DM are related to BMD and adipos-
ity. To our knowledge this is a first study performed on
human subjects with osteoporosis and diabetes type 2 in-
cluding patients with long-term diabetes who have received
standard care according to American Diabetes Association
(ADA) guidelines [14], thus all medications were carefully
recorded and the possible role of the subsequent modifica-
tion of inflammation/coagulation was investigated.
Methods
Study design
This study complied with the Declaration of Helsinki and
was approved by ethics committee of University Hospital
Center Osijek. Informed and written consent was obtained
from all participants. The subjects of this study were a
subset of all patients who visited the outpatient clinic for a
regular medical check-up or were hospitalized because of
poor metabolic control at the Department of Endocrinology
and Diabetes, Clinical Hospital Center Osijek. In this cross
sectional study a total of 117 postmenopausal female pa-
tients with diabetes type 2 were included and then divided
according to lumbar spine BMD (LBMD) measurements
via dual-energy x-ray absorptiometry (DXA) in three
groups: 47 with osteopenia (T-score between −1 and −2,5),
21 with osteoporosis (T-score ≤ −2,5) and 49 with normal
BMD (T-score of −1 or higher).
Patients
Inclusion citeria were as follows: female gender, diabetes
mellitus type 2 and menopause. Patients with a history
of the following conditions were excluded from the
study: those taking medication for osteoporosis; those
receiving medications affecting BMD, such as glucocorti-
coids; those with conditions, such as malignancy, thyroid
disease or thyroid functional abnormality, that would be
apparent causes for abnormal bone mass and those with
acute infectious disease or chronic inflammatory diseases.
At the time of inclusion detailed medical history was
obtained, physical exam and ECG was performed. Each
patient underwent DXA for assessment of bone mineral
density and BMI was calculated from body weight and
height (kg/m2). Waist circumference at the bending
point was measured in centimeters with the participant
wearing only a single layer of clothes. Postmenopausal
status was defined, through a close history taking, as
cessation of menstruation for at least 1 year.
BMD measurement
The BMD of the lumbar spine and total hip was measured
by dual energy X-ray absorptiometry (Dexa QDR 1000,
Hologic, Inc., Waltham, MA) calibrated daily using a
standard phantom provided by the manufacturer. Lumbar
spine BMD was the mean of lumbar vertebrae 1–4.
Biochemical assay
At study entry, all women underwent blood analyses to
verify a healthy state. All blood samples, incuding samples
for determing bone turnover markers, were obtained after
overnight fast. Blood samples were drawn to determine
routine laboratory tests including cholesterol, triglycerides,
HDL-C, LDL-C, urea, creatinine, HbA1c. Measurements of
plasma glucose, HbA1c, lipids, renal function and creatin-
ine clearance were performed by routine assays using
automatic analyzer Olympus AV 640 (Olympus, Beckman
Coulter, Inc). Insulin levels were measured by commercial
available radio-immunoassay (RIA) kit (SorinBiomedica,
Italy) according to manufacturer’s recommendations. Bone
metabolism was evaluated by determining the serum levels
of osteocalcin (OC) as marker of bone formation, and
urinary pyrilinks-D (PYD) and beta-CrossLaps (B-CTx), as
markers of bone resorption. Second morning urine sample
was collected and PYD in urine was measured using com-
petitive enzyme immunoanalysis by commercially available
kit, according to Manufacturer’s protocol (Metra Biosystem
INC., Mountain View, SAD, reference value 3.0–7.4 nM
DPD/mM creatinine). Serum OC levels were assayed by an
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immunoradiometric assay (IRMA) with commercially avail-
able kits, according to manufacturer’s recommendations
(BioSource Europe S.A., Nivelles, Belgium, reference value
5–25 ng/mL). Serum Beta-CTx was measured by electro-
chemiluminescent immunoassay (ECLIA) by commercially
available kit, according to Manufacturer’s protocol (Roche-
B-Crosslaps assay). Fibrinogen and plasminogen activator
inhibitor-1 (PAI-1) were determined by coagulometry using
automated photometric coagulation analyzer BCS (Behring
Coagulation System) X5.
Statistical analysis
Continuous variables were summarized using mean and
standard deviation values. Significance was declared at a
two-sided 0.05 level, unless otherwise specified. Mann–
Whitney test or parametric t-test was used for between
group comparisons. Analysis of variance (ANOVA) was
used to determine the significance of difference between
three groups. For data which was not normally distributed
analysis of variance was performed with Kruskal Wallis
ANOVA. Relationships between variables were analyzed
using Spearman’s coefficients of correlations. Stepwise
multiple regression analysis with forward selection was
used to examine the relationships among variables. Results
of regression analysis were given as beta coefficients and
R2. All statistical analysis was performed using the pro-
gram package StatSoft, Statistica12.0.
Results
Characteristics of diabetic postmenopausal women with
normal BMD compared to group with decreased BMD
Baseline characteristics of the subjects are summarized
in Table 1. All groups were similar in the diabetes dur-
ation and HbA1c levels. A total of 117 diabetic patients
were divided according to L-BMD measurements in
three groups: 47 with osteopenia (T-score between −1 to
−2,5), 21 with osteoporosis (T-score ≤ −2,5) and 49 with
normal BMD (T-score ≥ −1). Groups were matched
according to age, smoking, alcohol consumption, antihyper-
tensive and statin therapy as well as hormone replacement
therapy and oral antidiabetic drugs (Additional file 1: Table
S1). No one received pioglitazone nor SGLT2 inhibitors.
Diabetic patients with normal BMD had significantly higher
BMI (p = 0,02; p = 0,002 respectively) and greater waist
circumference (p = 0,03; p = 0,003 respectively) than dia-
betics with osteopenia and osteoporosis. They had shorter
menopause period (p = 0,049) and slightly but significantly
lower LDL cholesterol (p = 0,042) compared with diabetics
with osteoporosis. When compared to both groups with
bone loss, diabetics with normal BMD had significantly
lower bone turnover markers (p < 0,01). PAI-1 was the
Table 1 Baseline characteristics of postmenopausal women with T2DM
Osteoporosis n = 21 Osteopenia n = 47 Normal BMD n = 49 p
Age (year) 65,3 ± 10,2 67,4 ± 8,04 64,9 ± 8,7 NS
Waist (cm) 89,8 ± 11,2 96,0 ± 8,2 98,3 ± 12,0 c0,03; b0,003
BMI (kg/m2) 27,5 ± 5,6 29,1 ± 3,9 31,3 ± 5,1 a0,02; b0,002
Menopause duration (year) 17,8 ± 9,2 18,3 ± 8,5 14,7 ± 7,9 a0,049
Diabetes duration (year) 9,1 ± 6,3 12,2 ± 7,1 12,1 ± 7,3 NS
HbA1c (%) 10,2 ± 2,24 10,1 ± 1,59 9,95 ± 1,9 NS
Cholesterol (mmol/l) 5,45 ± 1,62 5,13 ± 1,25 4,97 ± 1,41 NS
HDL cholesterol (mmol/l) 1,29 ± 0,25 1,22 ± 0,25 1,19 ± 0,27 NS
LDL cholesterol (mmol/l) 3,39 ± 1,02 3,03 ± 1,02 2,76 ± 1,12 ab 0,042
Triglicerydes (mmol/l) 1,98 ± 1,32 1,96 ± 0,79 2,37 ± 1,43 NS
Osteocalcin (ng/ml) 10,22 ± 7,67 8,37 ± 3,84 6,32 ± 2,87 a0,025; b0,0013
Insulin (mIU/l) 8,94 ± 4,14 9,97 ± 4,82 10,62 ± 5,69 NS
Pyrilinks (nMPD/mMc) 7,8 ± 3,1 7,41 ± 2,9 5,5 ± 2,1 a0,001; b0,0015
Crosslaps (ng/ml) 0,54 ± 0,25 0,49 ± 0,29 0,35 ± 0,21 a0,012; b0,0092
PAI-1 (U/l) 3,3 ± 2,1 3,5 ± 2,1 4,4 ± 1,9 a0,042; b0,052
Fibrinogen (g/L) 4,1 ± 1,0 4,3 ± 0,8 4,0 ± 0,8 NS
CRP (mg/L) 5,77 ± 11,6 3,89 ± 3,67 3,74 ± 4,25 NS
Lumbar BMD (g/cm2) 0,707 ± 0,07 0,856 ± 0,04 1,036 ± 0,09 ab c<0,05
Hip BMD (g/cm2) 0,746 ± 0,13 0,838 ± 0,109 0,985 ± 0,147 ac b<0,05
Chi square test; BMD bone mineral density, BMI body mass index, HDL high density lipoprotein, LDL low density lipoprotein, PAI 1 plasminogen activator inhibitor
1. Bolded p values are significant.
aosteoporosis group vs. normal BMD group; bosteopenia vs. normal BMD group; costeoporosis vs. osteopenia group
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lowest in diabetic patients with osteoporosis (p < 0,05) and
slightly but not significantly lower in patients with osteope-
nia (p < 0,052) compared with diabetics with normal BMD.
Associations of PAI-1 levels with metabolic parameters,
BMD and bone turnover markers
PAI-1 positively correlated with lumbar BMD (p < 0,05)
and proximal femur BMD (p < 0,000) as well as BMI
(p < 0,000), insulin (p < 0,000) and triglycerides (p < 0,000)
while negative correlation was observed in relation to age
(p < 0,01), HDL cholesterol (p < 0,001), diabetes duration
(p < 0,002), beta cross laps (p < 0,002), pyrilinks (p < 0,002)
and osteocalcin (p < 0,002) (Table 2). The strongest ex-
planatory variables for PAI-1 in the multiple regression
analysis after adjusting for age and BMI among metabolic
parameters were insulin and triglycerides levels as well as
duration of diabetes. With the inclusion of drugs, only
beta blocker (BB) and angiotensin convertase enzyme
inhibitors/angiotensin receptor blockers (ACEi/ARB) ther-
apy significantly correlated with PAI-1 levels, while there
was no correlation with statin and metformin (Additional
file 1: Table S2).
If we look at bone markers in the multiple regression
analysis after adjusting for age and menopause duration,
negative association of pyrilinks and PAI-1 was present.
In addition, hip BMD positively correlated with PAI-1
activity (Additional file 1: Table S3).
In the stepwise forward regression analysis triglycerides,
insulin, waist circumference, diabetes duration, pyrilinks
and BB treatment remained significantly correlated with
PAI-1 after adjusting for age and BMI, but the correlation
between PAI-1 and hip BMD was no longer significant as
was the case with the correlation between PAI-1 and
ACEi/ARB therapy (Table 3). The positive association was
observed between PAI-1 level and triglycerides, insulin,
BMI and waist circumference as well as BB therapy while
significant negative correlation was present between PAI-1
activity and pyrilinks. Therefore, the strongest determi-
nants of PAI-1 activity were triglyceride and insulin levels
followed by pyrilinks and explained 57,4 % of the variabil-
ity of PAI-1.
Associations of lumbar bone mineral density with
metabolic parameters, PAI-1 and bone turnover markers
Association of BMD with metabolic parameters and
bone turnover markers are shown in Table 2. There
was significant correlation between L-BMD and insulin
which remained significant after adjusting for age and
BMI (Table 4.A). L-BMD correlated positively with
PAI-1, but after adjusting for age and BMI the associ-
ation between L-BMD and PAI-1 did not remain
significant. The strongest determinants of L-BMD were
osteocalcin and insulin levels (Table 4.A).
Associations of bone turn over markers with metabolic
parameters, BMD and PAI-1
Forward stepwise regression analysis was performed to
determine the strongest predictors of pyrilinks. The stron-
gest predictor of pyrilinks was L-BMD, followed by waist
circumference (Table 4.B). The association between pyri-
links and PAI-1 remained significant after adjusting for age
and BMI (p = 0,0126).
Forward stepwise regression analysis was performed to
determine the strongest predictors of osteocalcin. When
osteocalcin was entered as a dependent variable and waist
circumference, diabetes duration, menopause duration, in-
sulin, triglycerides, femoral and lumbar BMD, and therapy,
as independent variables, the strongest predictors of
osteocalcin were L-BMD, insulin and pyrilinks, R2 = 0,420,
p = 0,000001 (data not shown).
Table 2 Associations of PAI-1 levels and metabolic parameters, BMD and bone turnover markers; association of L-BMD and metabolic
parameters, PAI-1 and bone turnover markers
PAI-1 r p L-BMD r p
Age (year) −0,2375 0,011 Age (year)
BMI (kg/m2) 0,3453 0,000 BMI (kg/m2) 0,347 0,000
Diabetes duration (year) -0,3046 0,002 Diabetes duration (year) 0,297 0,000
Insulin (mIU/L) 0,4411 0,000 Insulin (mIU/L) −0,232 0,018
Triglycerides (mmol/L) 0,4704 0,000 Triglycerides (mmol/L)
HDL (mmol/L) -0,3331 0,001 LDL (mmol/L) -0,1956 0,041
Osteocalcin (ng/ml) -0,2976 0,002 PAI-1 0,119 0,046
Pyrilinks (nMPD/mMc) -0,2897 0,002 Osteocalcin (ng/ml) −0,318 0,001
Crosslaps (ng/ml) -0,2955 0,002 Pyrilinks (nMPD/mMc) −0,302 0,001
Lumbar BMD (g/cm2) 0,1990 0,046 Crosslaps (ng/ml) −0,24 0,012
Hip BMD (g/cm2) 0,3530 0,000
PAI 1 plasminogen activator inhibitor 1, BMD bone mineral density, BMI body mass index, HDL high density lipoprotein
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Discussion
It is generally considered that diabetes type 2 patients
have higher BMD compared to non-diabetic control
subjects [15], however, that particular population of
patients also has increased risk of fractures [16]. This
could be due to low grade inflammation which is more
severe in subjects with high insulin resistance than in
those with low insulin resistance [17, 18], presumably
leading to lower quality of bones causing higher inci-
dence of fractures despite normal BMD in diabetes type
2 patients. Therefore, a role of obesity and chronic
inflammation in diabetes type 2 still remains elusive.
Our research demonstrated that postmenopausal female
patients with diabetes type 2 and normal BMD had sign-
ficantly lower bone turnover markers and higher BMI
compared to diabetic subjects with osteoporosis/osteo-
penia indicating lower rate of bone turnover in obese
subjects. In addition to the well established role of in-
flammatory cytokines in promoting enhanced osteoclast
function and bone loss, proinflammatory cytokines may
also inhibit osteoblast function and bone repair [5].
Whereas previous work suggests that osteoporosis is
linked to inflammation, it is not yet clear whether higher
CRP levels are associated with bone loss [19]. In recently
published study CRP was associated inversely with com-
posite strength index but not associated with femoral
neck or lumbar spine BMD [20] which is consistent with
our observation.
There is growing evidence that disturbances in produc-
tion of plasminogen activator inhibitor 1, one of the pro-
inflammation markers, could be responsible for lower bone
quality in diabetic patients. Over-expression of PAI-1 in
transgenic mice resulted in increased mineralization and
biomechanical properties of mouse femora [12, 13]. How-
ever, there are no studies investigating a role of PAI-1 in
human subjects with osteoporosis and diabetes type 2. If
we look at PAI-1 levels in our study, a decreased concentra-
tion was observed in diabetic female subjects with lower
bone mineral density (the difference being greatest between
osteoporosis and normal BMD group) along with positive
correlation with lumbar and femoral BMD and negative
one with bone turnover markers, suggesting that increased
leves of PAI-1 could protect against bone loss in diabetes
type 2 female patients. However, if that assumption is true,
then why are PAI-1 levels decreased in diabetic patients
with osteoporosis compared to those with normal BMD?
We can only speculate, that lower levels of PAI-1 were due
to lower BMI. However, insulin levels were not significantly
lower in diabetic patients with osteoporosis, possibly due to
a relatively small number of subjects but consistently sig-
nificant positive correlation was found between insulin and
PAI after adjustment for age and BMI.
This notion is supported with previous findings where
increased levels of PAI-1 were present in the insulin
resistance syndrome, and a significant correlation was
found between plasma PAI-1 levels and body mass
Table 3 Stepward forward regression analysis of PAI-1 and
metabolic parameters, bone mineral density and therapy
Dependent variable: PAI-1 Beta p adjusted R2
Triglycerides (mmol/L) 0,314 0,0002 0,574
Insulin (mIU/L) 0,250 0,0033
Pyrilinks (nMPD/mMc) −0,308 0,0002
BMI (kg/m2) 0,310 0,0035
Waist circumference (cm) −0,278 0,0097
Age (years) −0,364 0,0201
Diabetes duration (years) −0,187 0,0185
Menopause duration (years) 0,283 0,0688
Beta blockers (%) 0,224 0,0045
PAI-1 plasminogen activator inhibitor 1, BMI body mass indeks
Table 4 Stepward forward regression analysis of lumbar BMD and metabolic parameters (A); stepward forward regression analysis of
pyrilinks and BMD and metabolic variables (B)
A: Dependent variable L-BMD Beta p B: Dependent variable Pyrilinks Beta p
Age (years) 0,716 0,0002
Menopause duration (years) −0,718 0,016
BMI (kg/m2) 0,279 0,0021 0,309 0,053
Waist circumference (cm) −0,381 0,011
Triglycerides (mmol/L)
Insulin (mIU/L) −0,273 0,009
PAI-1(U/l) 0,171 0,117 −0,274 0,0126
Pyrilinks (nMPD/mMc)
Osteocalcin (ng/ml) −0,391 0,0001
L-BMD (g/cm2) −0,319 0,0025
adjusted R2 0,408 0,00000 adjusted R2 0,251 0,0001
PAI-1 plasminogen activator inhibitor 1, BMI body mass index, L-BMD lumbar bone mineral density
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index, triglyceride levels, insulin levels and systolic blood
pressure [6, 7]. The possible mechanisms are still un-
clear and in-vitro data indicate that PAI-1 synthesis by
endothelial cells and hepatocytes could be affected by
insulin, proinsulin and atherogenic lipoproteins [21]. In
our study, in the final regression analysis triglycerides,
insulin, BMI and waist circumference significantly corre-
lated with PAI-1 levels, whereas correlation of PAI-1 and
BMD did not exist. In addition, bone turnover markers
accounted for only 16 % of variance in PAI-1 levels,
while metabolic parameters accounted for 39 % of total
variance in the multiple regression analysis, implying that
the influence of bone markers on PAI-1 levels was weaker
compared to metabolic parameters. These results suggest
that PAI-1 correlated primarily with metabolic parameters
such as hyperinsulinemia, hypertriglyceridemia, obesity
and adipose distribution, while association of PAI-1 and
BMD and bone turnover was weaker. After adjustment for
age and BMI, the association between PAI and both lum-
bar BMD and hip BMD was no longer significant, suggest-
ing that metabolic parameters may affect both BMD and
PAI-levels. Therefore, the association of PAI-1 and lumbar
BMD could be only indirect. However, one of the bone
resorption markers (pyrilinks) was independently and
significantly negatively associated with PAI-1. Obviously,
interaction between bone, body composition, endocrine,
and inflammatory systems is complex and the underlaying
mechanism of PAI influence on the bone remains unclear.
This effect could be mediated through protective mecha-
nisms of obesity and hyperinsulinemia in diabetes type 2
on bone mass, since the strongest determinants of circu-
lating levles of PAI-1 were insulin and tryglicerides leveles,
thus prevailing over deleterious effect of chronic inflam-
mation on bone metabolism (4,5).
Postmenopausal women included in this study were all
long term diabetes type 2 patients receiving standard care
according to ADA recommendations [14]. Since majority
of those medications could alter PAI-1 levels, the possible
effect of drugs was also investigated. It is a known fact that
lowering PAI-1 levels may be achieved by diet and/or
exercise or by treatment with thiazolidinediones, metfor-
min, statins or inhibitors of the renin–angiotensin system
[22]. However, our data did not confirm those results. In
the regression analysis model, only beta blocker therapy
and ACEi/ARB significantly correlated with PAI-1 levels,
while there was no correlation with statin and metformin
therapy as was expected. This discrepancy could be
explained with small sample size to obtain statistical sig-
nificance, although according to previous studies, beta
blockers have prothrombotic effect, and in fact increase
PAI level [23] which is consistent with our results. In this
study, PAI levels were not affected by statins nor metfor-
min with the exception of beta blockers and ACEi/ARB,
but usage of these drugs were not randomized. This
supports the notion that various drugs have effect on
circulating PAI-1 levels, however this is a real life study
and an indicator for further research that the influence of
therapy should not be ignored.
Our study has some limitations. A first limitation of
our study is the cross-sectional design, which limits the
assessment of causal relationships. A second limitation is
the relatively small sample size of diabetic patients with
respect to the complex questions addressed, especially
after stratification according to BMD in three groups.
Furthermore, this article does not assess fracture risk
which is especially important in diabetic patients who
presumably have lower quality of bone in spite of higher
BMD as was stated previously [15, 16].
Conclusion
In conclusion, this a first study investigating a role of PAI-
1 in human subjects with osteoporosis and diabetes type
2. Our findings suggest that elevated PAI-1 levels are
associated with higher BMD in obese diabetic patients but
the possible implications of this finding and underlaying
mechanisms still remain unclear. Obviously influence of
PAI is primarily mediated through metabolic factors,
hyperinsulinemia, hypertriglyceridemia, and obesity. How-
ever, the fact that pyrilinks also independently correlates
to PAI-1 may suggest its direct involvement in bone
metabolism influencing bone mass and strength. In con-
clusion PAI-1 appears to be a marker of metabolic status
that correlates with measures of bone density and turn-
over; whether it is itself an agent that affects bone would
need to be investigated in further studies.
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